The Life Sciences team advised Scholar Rock as it closed a $47 million Series C financing round to advance SRK-015, the company’s lead clinical candidate for Spinal Muscular Atrophy (SMA) and other neuromuscular disorders. The financing was led by new investor Invus, with the participation of new investor Redmile Group. All of the existing investors in Scholar Rock also participated in this financing round, including Polaris Partners, Timothy Springer, ARCH Venture Partners, EcoR1 Capital, The Kraft Group, Fidelity Management and Research Company, and Cormorant Asset Management.
Scholar Rock is discovering and developing a pipeline of innovative new medicines to treat a range of serious diseases in which growth factors play a fundamental role, including neuromuscular diseases, cancer and fibrosis.
The Goodwin team was led by partner included partners Kingsley Taft and Daniel Karelitz.
For additional details on the financing, please read the press release.
Scholar Rock is discovering and developing a pipeline of innovative new medicines to treat a range of serious diseases in which growth factors play a fundamental role, including neuromuscular diseases, cancer and fibrosis.
The Goodwin team was led by partner included partners Kingsley Taft and Daniel Karelitz.
For additional details on the financing, please read the press release.